Lucid Diligence Brief: Stipple Bio $100 million Series A
Lucid Diligence Brief: Stipple Bio $100 million Series A Professional audiences…
Lucid Diligence Brief: Syneron Bio completion of $150 million Series B
Lucid Diligence Brief: Syneron Bio completion of $150 million Series B…
Lucid Diligence Brief: Eli Lilly acquires Centessa Pharmaceuticals
Lucid Diligence Brief: Eli Lilly acquires Centessa Pharmaceuticals Professional…
Lucid Diligence Brief: CellCarta and Pillar Biosciences strategic partnership
Lucid Diligence Brief: CellCarta and Pillar Biosciences strategic partnership…
Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1 asset
Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1……
Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D deal for JNJ-4804
Lucid Diligence Brief: Royalty Pharma and J&J partner in a $500M R&D…
AI in Healthcare and Digital Health Today—March 30, 2026
This week’s Artificial Intelligence and Digital Health update highlights…
Lucid Diligence Brief: InSilico Medicine and Lilly global partnership
Lucid Diligence Brief: InSilico Medicine and Lilly global partnership…
Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics
Lucid Diligence Brief: Otsuka to acquire Transcend Therapeutics Professional…
Lucid Diligence Brief: AstraZeneca's tozorakimab meets primary endpoint in COPD
Lucid Diligence Brief: AstraZeneca's tozorakimab meets primary endpoint in……
Lucid Diligence Brief: Pinnacle Medicines $89 million Series B
Lucid Diligence Brief: Pinnacle Medicines $89 million Series B Professional…
Lucid Diligence Brief: MSD to acquire Terns
Lucid Diligence Brief: MSD to acquire Terns Professional audiences only. Not…


